NOV 05, 2015 07:15 AM PST

Theranos' Bloody Battle

With an estimated value at $9 billion, Theranos is, by all rights, not an average multi-billion dollar biotech startup. Going completely against the notion of “bigger is always better,” the company was founded on the idea of blood testing using just a few droplets via a finger prick. They claimed that over 100 blood tests could be done on just a few blood droplets. Their “less is more” approach extended to costs per test, advertising over 150 tests offered at less than $10.
Founder Elizabeth Holmes holds Theranos' nanotainer device
In an era of increasingly exorbitant health-care costs, Theranos’ ideas were deemed revolutionary and drew in massive funding support by the venture capitalists. But the eager hype surrounding Theranos has recently shifted into rowdy discomfort.

In a damning exposition published by the Wall Street Journal, Theranos was alleged to have stopped droplet blood collection via finger pricks for all but one out of the 240 tests it offers. The implication is that nearly all of Theranos’ blood collection is performed via traditional venipuncture, a method that collects blood in the volume of milliliters. If true, this stark contradiction could compromise the entire integrity of the droplet idea on which the company was founded.
As an even bigger cause for concern, results from blood test performed by Theranos are being seriously questioned for accuracy and legitimacy. In addition to independent reports of discrepant test results, a recent investigative report by the Food and Drug Administration (FDA) cited lack of quality audits for the medical device and laboratory tests offered by Theranos.
Another big deficiency cited by the FDA is Theranos’ unapproved use of the Capillary Tube Nanotainer (CTN), their proprietary blood collection device. While Theranos claimed the CTN to be a Class I device, the FDA classified it as a Class II Medical Device, requiring more rigorous regulatory and performance standards, which Theranos has yet to meet.  
Arguably the challenges facing Theranos are complex, as this company is involved in two related steps of clinical diagnostics: it is the manufacturer of a clinical device, and it is a clinical laboratory provider of diagnostic services. This means that Theranos has a dual burden of complying with two regulatory bodies: the FDA and the Clinical Laboratory Improvement Amendments (CLIA). As the developer, manufacturer, and user of the CTN, Theranos must comply with FDA standards for the production and post-market surveillance of the CTN as a Class II medical device. In addition, as a clinical laboratory performing diagnostic tests, Theranos has to satisfy the Clinical Laboratory Improvement Amendments (CLIA) requirements for each of the clinical test it offers.
While there are some overlaps between the FDA and CLIA, Theranos must demonstrate compliance with both sets of regulations. And so far, Theranos’ FDA report card is less than desirable. Its CLIA report is yet to be made public.
With the controversies surrounding Theranos, would you want the company to prick your finger? And would you trust the accuracy of their test results? Walgreens, the U.S. drugstore giant, is having some serious doubts, too. Amidst Theranos’ bloody storm, Walgreens has put a stop on the opening of additional Theranos Wellness Centers inside its pharmacies, stating that “Plans to open more Theranos Wellness Centers are dependent upon both companies’ ability to reach a mutually beneficial arrangement.”
Not surprisingly, the embattled founder and CEO of Theranos, Elizabeth Holmes, is fighting hard to regain control. She has rebutted all allegations and stood firm behind her company and its promises. But Theranos’ critics are not appeased. Is Theranos’ fall from grace imminent? Only time can tell. But one thing is for certain, with many questions still unanswered and FDA citations still fresh, the scrutiny on Theranos will only intensify.
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at
You May Also Like
OCT 19, 2019
Health & Medicine
OCT 19, 2019
Fourth-Generation Rapid Diagnostic Tests for Acute HIV-1 Infections
The ability to diagnose an acute HIV-1 infection before there are detectable antibodies to HIV 1/2 is critical to making an early diagnosis and getting the...
OCT 19, 2019
Clinical & Molecular DX
OCT 19, 2019
Easy detection of ear infection in kids using a smartphone app
Acute Otitis Media (AOM) a middle ear infection is a very common ear disease in kids. The main symptoms are middle ear inflammation, pain, irritability, or...
OCT 19, 2019
OCT 19, 2019
Fibromyalgia Linked to Gut Microbes
Using clinical samples, scientists identified differences in the microbial population in the guts of people with fibromyalgia....
OCT 19, 2019
OCT 19, 2019
The brain of a psychopath: how people with psychopathic traits control their 'dark urges'
Psychopaths are usually portrayed negatively: they display antisocial behavior, such as shallow emotions, callousness, impulsivity, and lack of empathy. Ps...
OCT 19, 2019
OCT 19, 2019
Flu Shot Less Effective Due to Overuse of Antibioitics
New research out of the Stanford University School of Medicine shows that the consequence of overuse of antibiotics lowers the effectiveness of the seasona...
OCT 19, 2019
Genetics & Genomics
OCT 19, 2019
A 'Molecular Clock' for Determining a Child's Age
This tool can aid in the diagnosis of developmental disorders, including autism spectrum disorder....
Loading Comments...